Rheumatoid arthritis and COVID-19: Three years later
暂无分享,去创建一个
[1] P. Raghav,et al. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions , 2023, Journal of Pharmacological Sciences.
[2] A. Skapenko,et al. COVID-19 vaccination in individuals with inflammatory rheumatic diseases , 2022, Nature Reviews Rheumatology.
[3] T. Bergquist,et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C) , 2022, Seminars in Arthritis and Rheumatism.
[4] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5 , 2022, Arthritis & rheumatology.
[5] J. Sparks,et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study , 2022, Seminars in Arthritis and Rheumatism.
[6] J. Sparks,et al. Risk of COVID‐19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study , 2022, Arthritis care & research.
[7] N. Muravyeva,et al. Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases , 2022, Antibiotics and Chemotherapy.
[8] R. Xavier,et al. Update to “guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force” , 2022, Advances in Rheumatology.
[9] A. Eftekharsadat,et al. Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination , 2022, International Immunopharmacology.
[10] M. Kudo,et al. Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination , 2022, Frontiers in Immunology.
[11] J. Sparks,et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study , 2022, Seminars in Arthritis and Rheumatism.
[12] C. Torp‐Pedersen,et al. COVID-19 infection and hospitalisation risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis , 2022, Rheumatology.
[13] Matthew D. Li,et al. Assessing the Severity of COVID‐19 Lung Injury in Rheumatic Diseases versus the General Population Using Deep Learning‐Derived Chest Radiograph Scores , 2022, Arthritis care & research.
[14] P. Sfikakis,et al. Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study , 2022, medRxiv.
[15] M. Merad,et al. The immunology and immunopathology of COVID-19 , 2022, Science.
[16] A. Lila,et al. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues , 2022, Rheumatology Science and Practice.
[17] M. Merad,et al. Pathological sequelae of long-haul COVID , 2022, Nature Immunology.
[18] J. Sparks,et al. Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy , 2022, RMD Open.
[19] M. Netea,et al. A guide to immunotherapy for COVID-19 , 2022, Nature Medicine.
[20] D. Ye,et al. New‐onset autoimmune phenomena post‐COVID‐19 vaccination , 2021, Immunology.
[21] A. Lila,et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review , 2021, Rheumatology Science and Practice.
[22] C. Zeng,et al. Increased Risk of COVID‐19 in Patients With Rheumatoid Arthritis: A General Population‐Based Cohort Study , 2021, Arthritis care & research.
[23] M. Konig,et al. SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis , 2021, Arthritis & rheumatology.
[24] Andreas Krause,et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD , 2021, RMD Open.
[25] L. Trupin,et al. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19 , 2021, JAMA network open.
[26] E. Nasonov,et al. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) , 2021, Rheumatology Science and Practice.
[27] C. Kavadichanda,et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States , 2021, Seminars in Arthritis and Rheumatism.
[28] J. Yazdany,et al. Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al , 2021, Annals of the Rheumatic Diseases.
[29] A. Baranov,et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia , 2021, Rheumatology Science and Practice.
[30] J. G. Ryan,et al. Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry , 2021, Rheumatology advances in practice.
[31] K. Michaud,et al. Risk of COVID‐19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At‐Risk Individuals , 2021, Arthritis & rheumatology.
[32] David A. Drew,et al. Attributes and predictors of long COVID , 2021, Nature Medicine.
[33] Jianbo Liu,et al. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis , 2021, Rheumatology International.
[34] E. Nasonov. Coronavirus disease 2019 (COVID-19) and autoimmunity , 2021, Rheumatology Science and Practice.
[35] M. Gianfrancesco,et al. Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al , 2021, Annals of the Rheumatic Diseases.
[36] C. Turesson,et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study , 2021, Annals of the Rheumatic Diseases.
[37] Anonymous. Correction: High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry , 2021, RMD Open.
[38] S. Villapol,et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.
[39] P. Brodin. Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.
[40] H. Lorenz,et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases , 2021, RMD Open.
[41] C. Torp‐Pedersen,et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark , 2020, Rheumatology.
[42] Hyon K. Choi,et al. COVID‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study , 2020, Arthritis & rheumatology.
[43] Florence Nassim Jean-David Didier Yannick Blanca Zahir Emma Aeschlimann Ait-Abdallah Albert Alcais A. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients , 2020, Annals of the Rheumatic Diseases.
[44] E. Nasonov,et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity , 2020, Rheumatology Science and Practice.
[45] E. Nasonov,et al. The role of Interleukin 6 inhibitors in therapy of severe COVID-19 , 2020, Biomedicine & Pharmacotherapy.
[46] A. Ogdie,et al. COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes , 2020, Arthritis & rheumatology.
[47] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[48] L. Trupin,et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.
[49] Евгений Львович Насонов. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога , 2020 .
[50] Georg Schett,et al. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? , 2020, Nature Reviews Immunology.
[51] P. Lipsky,et al. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases , 2019, Nature Reviews Rheumatology.
[52] W. Dixon,et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative , 2016, Annals of the rheumatic diseases.
[53] OUP accepted manuscript , 2021, Rheumatology.